Psilocybin
- Generic Name
- Psilocybin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N2O4P
- CAS Number
- 520-52-5
- Unique Ingredient Identifier
- 2RV7212BP0
- Background
Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.
- Associated Conditions
- -
- Associated Therapies
- -
The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Maryland Oncology Hematology, PA
- Target Recruit Count
- 30
- Registration Number
- NCT04593563
- Locations
- πΊπΈ
Maryland Oncology Hematology PA, Rockville, Maryland, United States
Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 12
- Registration Number
- NCT04522804
- Locations
- πΊπΈ
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 21
- Registration Number
- NCT04505189
- Locations
- π¬π§
Imperial College Hammersmith campus, London, United Kingdom
Precision Functional Brain Mapping in Psilocybin
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 11
- Registration Number
- NCT04501653
- Locations
- πΊπΈ
Washington University, Saint Louis, Missouri, United States
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Sheppard Pratt Health System
- Target Recruit Count
- 27
- Registration Number
- NCT04433858
- Locations
- πΊπΈ
VA Palo Alto Healthcare System/Stanford Medicine, Palo Alto, California, United States
πΊπΈSheppard Pratt Health System, Baltimore, Maryland, United States
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Sheppard Pratt Health System
- Target Recruit Count
- 15
- Registration Number
- NCT04433845
- Locations
- πΊπΈ
Sheppard Pratt, Baltimore, Maryland, United States
Visual Surround Suppression and Perceptual Expectation Under Psilocybin
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 10
- Registration Number
- NCT04424225
- Locations
- πΊπΈ
University of Minnesota, Minneapolis, Minnesota, United States
Prophylactic Effects of Psilocybin on Chronic Cluster Headache
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Gitte Moos Knudsen
- Target Recruit Count
- 10
- Registration Number
- NCT04280055
- Locations
- π©π°
Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark
Comparative Acute Effects of LSD, Psilocybin and Mescaline
- Conditions
- Interventions
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 32
- Registration Number
- NCT04227756
- Locations
- π¨π
University Hospital Basel, Clinical Trial Unit, Basel, BS, Switzerland
Repeat Dosing of Psilocybin in Migraine Headache
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Yale University
- Target Recruit Count
- 18
- Registration Number
- NCT04218539
- Locations
- πΊπΈ
VA Connecticut Healthcare System, West Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.